top of page

SUBSCRIBE TO OUR NEWSLETTER

PARSIFAL

STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB IN COMBINATION WITH FULVESTRANT OR LETROZOLE IN PATIENTS WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER.

https://clinicaltrials.gov/ct2/show/NCT02491983

HR+ HER2neg ABC

50

486

II

Spain, France, Italy, UK, Germany, Russia, Czech Republic

Closing

CLINICAL TRIAL DETAILS

A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE II TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB IN COMBINATION WITH FULVESTRANT OR LETROZOLE IN PATIENTS WITH HER2 NEGATIVE, ER+ METASTATIC BREAST CANCER.

THIS IS AN INTERNATIONAL, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTICENTER PHASE II CLINICAL TRIAL TO INVESTIGATE AND COMPARE THE SAFETY AND EFFICACY OF PALBOCICLIB COMBINED WITH FULVESTRANT OR LETROZOLE IN WOMEN WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER.

TUMOR TYPE

PHASE

N

SITES

COUNTRY

STATUS

PRESS RELEASE

2021 Press Release: https://www.medsir.org/post/parsifal-study-breast | SABCS 2023 - PARSIFAL-LONG Press Release: https://www.medsir.org/post/press-release-parsifal-long-at-san-antonio-breast-cancer-symposium

SCIENTIFIC IMPACT

SABCS 2023 PARSIFAL-LONG substudy presentation: https://www.medsir.org/_files/ugd/39f166_0415b0b8493f4299b7899f522f0f7a75.pdf | SABCS 2023 PARSIFAL-LONG substudy lay summary: https://www.medsir.org/_files/ugd/39f166_d1701f56c6464c03b5752aa7590b3d32.pdf | SABCS 2023 DNADX PARSIFAL substudy poster: https://www.medsir.org/_files/ugd/39f166_83e3fa76cd4949e6b1c73d2105bf6844.pdf | SABCS 2023 DNADX PARSIFAL substudy lay summary: https://www.medsir.org/_files/ugd/39f166_4c05158e86d844bc80556f7484b46eb3.pdf | The Oncologist 2023: https://academic.oup.com/oncolo/article/28/1/23/6761067 | JAMA Oncology 2021: https://jamanetwork.com/journals/jamaoncology/article-abstract/2784608 | SABCS 2022 poster: https://d9ec78c0-6610-4e58-b628-a2262f2019e2.usrfiles.com/ugd/d9ec78_d2ca7772eb944784ad640fb924c7c651.pdf | SABCS 2020 poster: https://39f1664e-7766-40bf-9b5a-e3575d54bba6.usrfiles.com/ugd/39f166_a3b026acabaa458cbdebb5d6dd6a4d7a.pdf | ASCO 2020 abstract: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.1007 | ESMO 2016 poster: https://39f1664e-7766-40bf-9b5a-e3575d54bba6.usrfiles.com/ugd/39f166_c001f5df16dc40be8ba56986217db0dc.pdf

BLOG ARTICLES RELATED

Spotlight - LUPER small-cell lung cancer trial: https://www.medsir.org/post/spotlight-luper-small-cell-lung-cancer-trial | It was great to be back at ASCO!: https://www.medsir.org/post/it-was-great-to-be-back-at-asco | We’re presenting at ASCO 2022!: https://www.medsir.org/post/we-re-presenting-at-asco-2022 | PARSIFAL: Identifying an endocrine agent for palbociclib in endocrine sensitive ABC: https://www.medsir.org/post/parsifal-identifying-an-endocrine-agent-for-palbociclib-in-endocrine-sensitive-abc | Interview with Dr. Llombart on OncologyTube on the PARSIFAL and BIOPER studies presented at SABCS: https://www.medsir.org/post/interview-with-dr-llombart-on-oncologytube-on-the-parsifal-and-bioper-studies-presented-at-sabcs | Final safety results of our PARSIFAL study were presented at SABCS 2020: https://www.medsir.org/post/final-safety-results-of-our-parsifal-study-were-presented-at-sabcs-2020 | SABCS 2020: Final results of PARSIFAL and BIOPER clinical trials to be presented: https://www.medsir.org/post/sabcs-2020-final-results-of-parsifal-and-bioper-clinical-trials-to-be-presented | Results of the PARSIFAL study to be presented at the SEOM Conference 2020: https://www.medsir.org/post/results-of-the-parsifal-study-to-be-presented-at-the-seom-conference-2020 | SEOM 2020\: Results from the Spanish cohort of the MEDSIR-sponsored study PARSIFAL: https://www.medsir.org/post/seom-2020-results-from-the-spanish-cohort-of-the-medsir-sponsored-study-parsifal | PARSIFAL clinical trial results presented at ASCO Annual Meeting: https://www.medsir.org/post/parsifal-clinical-trial-results-presented-at-asco-annual-meeting | MedSIR to present results of clinical trials PHERGain and PARSIFAL at ASCO 2020: https://www.medsir.org/post/medsir-to-present-results-of-clinical-trials-phergain-and-parsifal-at-asco-2020 | Last Patient Last Visit for Final Analysis in PARSIFAL Study!: https://www.medsir.org/post/last-patient-last-visit-for-final-analysis-in-parsifal-study | PARSIFAL Study Status: https://www.medsir.org/post/parsifal-study-status | PARSIFAL: News: https://www.medsir.org/post/parsifal-news

PHERGAIN SITES

Dr. Cortes and Dr. Llombart PHERain interview

Beyond Chemotherapy

Dr. Vanes Quiroga

Dr. Sofia Braga

Dr. Silvi Antolín

Dr. Escrivá de Romaní

Dr. Philipp Aftimos

Dr. Manuel Ruiz

Prof. Daniele Generali PHEGain interview

Dr. Jacques Medioni

Dr. Dunca Wheatley

bottom of page